It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Phagocytosis of invading pathogens or cellular debris requires a dramatic change in cell shape driven by actin polymerization. For antibody-covered targets, phagocytosis is thought to proceed through the sequential engagement of Fc-receptors on the phagocyte with antibodies on the target surface, leading to the extension and closure of the phagocytic cup around the target. We find that two actin-dependent molecular motors, class 1 myosins myosin 1e and myosin 1f, are specifically localized to Fc-receptor adhesions and required for efficient phagocytosis of antibody-opsonized targets. Using primary macrophages lacking both myosin 1e and myosin 1f, we find that without the actin-membrane linkage mediated by these myosins, the organization of individual adhesions is compromised, leading to excessive actin polymerization, slower adhesion turnover, and deficient phagocytic internalization. This work identifies a role for class 1 myosins in coordinated adhesion turnover during phagocytosis and supports a mechanism involving membrane-cytoskeletal crosstalk for phagocytic cup closure.
Phagocytosis of pathogens is thought to proceed through the sequential engagement of Fc-receptors on the phagocyte with antibodies on the target surface. Here authors show that myosin 1e and myosin 1f link the actin cytoskeleton to the membrane and are required for efficient phagocytosis of antibody-opsonized targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Reilly, Nicholas S 2 ; Shutova, Maria S 3 ; Li Qingsen 4 ; Maiuri Paolo 4
; Heddleston, John M 5
; Mooseker, Mark S 6 ; Flavell, Richard A 7
; Svitkina Tatyana 3 ; Oakes, Patrick W 8
; Krendel Mira 1
; Gauthier, Nils C 4 1 State University of New York Upstate Medical University, Cell and Developmental Biology Department, Syracuse, USA (GRID:grid.411023.5) (ISNI:0000 0000 9159 4457)
2 University of Rochester, Department of Physics, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174)
3 University of Pennsylvania, Department of Biology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
4 FIRC Institute of Molecular Oncology, IFOM, Milan, Italy (GRID:grid.7678.e) (ISNI:0000 0004 1757 7797)
5 Howard Hughes Medical Institute Janelia Research Campus, Advanced Imaging Center, Ashburn, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)
6 Yale University, Molecular, Cellular and Developmental Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
7 Yale University School of Medicine, Department of Immunobiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Howard Hughes Medical Institute, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
8 University of Rochester, Department of Physics, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174); University of Rochester, Department of Biology, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174)




